{
    "clinical_study": {
        "@rank": "33685", 
        "brief_summary": {
            "textblock": "To evaluate the safety and tolerance, in patients with severe clinical manifestations of HIV\n      infection, of zidovudine (AZT) administered daily for 48 weeks as a low dose every 4 hours\n      or a higher dose every 12 hours."
        }, 
        "brief_title": "Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n        - Prophylaxis or treatment for Pneumocystis carinii pneumonia (PCP) consisting of either\n        trimethoprim / sulfamethoxazole, aerosolized pentamidine, pyrimethamine / sulfadoxine, or\n        dapsone  allowed at the discretion of the investigator.\n\n        Patients with the following are excluded:\n\n          -  Any immediately life-threatening infection or medical condition present at the time\n             of study entry.\n\n          -  Any active opportunistic or other infection requiring chronic therapy at the time of\n             study entry.  Patients with PCP may be randomized to study medication following a\n             minimum 7-day course of therapy resulting in stabilization of their disease. Patients\n             with stabilized disease must have a fever < 39 C for at least 48 hours, pO2 (on room\n             air ) = or > 60 mm, and an Arterial/alveolar gradient = or < 30 mm.\n\n          -  Diagnosis of AIDS Dementia Complex.\n\n          -  Received more than 4 weeks of antiretroviral therapy or who previously discontinued\n             antiretroviral therapy due to drug related toxicity.\n\n          -  Diseases and conditions listed in Exclusion Co-existing Conditions.\n\n        Patients must have the following:\n\n          -  Seropositive for HIV infection documented by any federally licensed ELISA and\n             confirmed by Western blot.\n\n          -  Advanced HIV disease or AIDS-related complex.\n\n          -  Ability to give informed consent.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  AIDS with malignant disease likely to require cytotoxic chemotherapy.\n\n          -  Diagnosis of AIDS Dementia Complex.\n\n          -  Impaired renal function ( Creatinine clearance < 50 ml/min/1.73m2 or serum creatinine\n             = or > 2 mg/dl).\n\n          -  Impaired hepatic function ( ALT = or > 5 x upper limit of normal).\n\n          -  Fever > 39 C at entry.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Any other experimental therapy.\n\n          -  Drugs which cause significant bone marrow suppression.\n\n          -  Cytolytic chemotherapy.\n\n          -  Drugs which cause significant nephrotoxicity or hepatotoxicity.\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Radiation therapy (with the exception of electron beam therapy to an area < 100 cm2).\n\n        Prior Medication:\n\n        Excluded within 2 weeks of study entry:\n\n        - Any other experimental therapy. Drugs which cause significant bone marrow suppression.\n        Cytolytic chemotherapy. Drugs which cause significant nephrotoxicity or hepatotoxicity.\n\n        Excluded within 4 weeks of entry:\n\n        - Immunomodulating agents, including pharmacological doses of steroids for more than 10\n        days (except for management of severe PCP in which case duration should not exceed 21\n        days). Interferon. Isoprinosine. IL-2.\n\n        Excluded within 8 weeks of entry:\n\n        -\n\n        Antiretroviral agents including:\n\n        - Ribavirin. Dideoxycytidine (ddC). Dideoxyadenosine (ddA). Didanosine (ddI). Foscarnet.\n        Dextran Sulfate. AL-721. Retrovir (Zidovudine, AZT) for greater than 4 weeks or within 90\n        days of study entry, or patients who originally discontinued Retrovir due to drug-related\n        toxicity. Drugs metabolized by hepatic glucuronidation may alter the metabolism of\n        Retrovir and should not be used chronically.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Radiation therapy (with the exception of electron beam therapy to an area < 100 cm2)\n             within 2 weeks of study entry.\n\n        Known active drug or alcohol abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "13 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002020", 
            "org_study_id": "014L", 
            "secondary_id": "28"
        }, 
        "intervention": {
            "intervention_name": "Zidovudine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Zidovudine"
        }, 
        "keyword": [
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Zidovudine"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85724"
                    }, 
                    "name": "Univ of Arizona / Health Science Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Rush Presbyterian - Saint Luke's Med Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Northwestern Univ Med School"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60612"
                    }, 
                    "name": "Cook County Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "64108"
                    }, 
                    "name": "Univ of Missouri at Kansas City School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newark", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "071032842"
                    }, 
                    "name": "North Jersey Community Research Initiative"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico", 
                        "zip": "87131"
                    }, 
                    "name": "Univ of New Mexico Hlth Sciences Ctr / Dept of Med"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manhasset", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11030"
                    }, 
                    "name": "Northshore Hosp / Cornell Univ"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Univ of Pennsylvania / HIV Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Galveston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77550"
                    }, 
                    "name": "Univ TX Galveston Med Branch"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Baylor College of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Juan", 
                        "country": "Puerto Rico", 
                        "zip": "009275800"
                    }, 
                    "name": "San Juan Veterans Administration Med Ctr"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Puerto Rico"
            ]
        }, 
        "official_title": "Trial of an Alternative Dosing Regimen of Oral Retrovir in Patients With AIDS or Advanced ARC", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002020"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 1992"
    }, 
    "geocoordinates": {
        "Baylor College of Medicine": "29.76 -95.369", 
        "Cook County Hosp": "41.878 -87.63", 
        "North Jersey Community Research Initiative": "40.736 -74.172", 
        "Northshore Hosp / Cornell Univ": "40.798 -73.7", 
        "Northwestern Univ Med School": "41.878 -87.63", 
        "Rush Presbyterian - Saint Luke's Med Ctr": "41.878 -87.63", 
        "San Juan Veterans Administration Med Ctr": "18.466 -66.106", 
        "Univ TX Galveston Med Branch": "29.301 -94.798", 
        "Univ of Arizona / Health Science Ctr": "32.222 -110.926", 
        "Univ of Missouri at Kansas City School of Medicine": "39.1 -94.579", 
        "Univ of New Mexico Hlth Sciences Ctr / Dept of Med": "35.084 -106.651", 
        "Univ of Pennsylvania / HIV Clinic": "39.952 -75.164"
    }
}